Related Experiment Videos
Oral contraception and breast pathology
Acta Europaea Fertilitatis
|June 1, 1981
Summary
Oral contraceptives significantly lower the risk of benign breast disease, likely due to progestin. Studies confirm this protective effect, but further research is needed on hormonal contraception and breast cancer links.
Area of Science:
- Reproductive Health
- Oncology
- Epidemiology
Background:
- The relationship between hormonal contraception and breast health is a significant area of research.
- Existing literature suggests a potential protective effect of oral contraceptives against benign breast conditions.
Purpose of the Study:
- To review international literature on the effects of oral contraceptives on breast disease.
- To analyze patient data from the Center for the Diagnosis and Prevention of Breast Cancer in Genoa.
- To evaluate the impact of hormonal contraception on both benign and malignant breast pathology.
Main Methods:
- Comprehensive review of human, animal, histological, and epidemiological data.
- Analysis of a cohort of 3527 patients (1977-1980) at the S. Martino Hospital, Genoa.
- Examination of retrospective and prospective studies on hormonal contraception and breast pathology.
Main Results:
- International literature and the Genoa study confirm that oral contraceptives reduce the risk of benign breast disease.
- The protective effect appears linked to the progestin component of oral contraceptives.
- Data on malignant breast pathology and hormonal contraception are presented, highlighting areas for further investigation.
Conclusions:
- Hormonal contraception, particularly oral contraceptives containing progestin, demonstrates a protective effect against benign breast pathology.
- Further research is essential to definitively clarify the complex relationship between combined estrogen-progestin (estroprogestins) and the risk of breast cancer.